Contrasting NewLink Genetics (NASDAQ:NLNK) and Editas Medicine (EDIT) – Dispatch Tribunal
|
Contrasting NewLink Genetics (NASDAQ:NLNK) and Editas Medicine (EDIT)
Dispatch Tribunal It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … |
